Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 9/20 | 0.63 |
| ▸ | SCNN1A | P37088 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | GLA | P06280 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamil SCHEMBL5433990 | 1.00 | PLAU (0.63) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| Benzamil SCHEMBL412783 | 1.00 | PLAU (0.63) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| Benzamil SCHEMBL9464171 | 0.99 | PLAU (0.64) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| SCHEMBL11615365 | 0.94 | PLAU (0.59) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| SCHEMBL10028719 | 0.85 | SCNN1A (0.61) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| 3',4' Dichlorobenzamil SCHEMBL14504158 | 0.85 | HSD17B10 (0.60) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| SCHEMBL5065784 | 0.83 | KCNH2 (0.51) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| SCHEMBL5014171 | 0.82 | SCNN1A (0.52) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| Phenamil SCHEMBL14504131 | 0.81 | PLAU (0.58) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| Phenamil SCHEMBL14973571 | 0.81 | PLAU (0.58) | PLAUSCNN1AALDH1A1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0451130-A2 | Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization | CELTRIX PHARMACEUTICALS, INC. (US) | 1991-10-09 | — | — | EP | claimed |
| US-20090253714-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R | 2009-10-08 | — | — | US | disclosed |
| US-7056524-B2 | Methods of hydrating mucosal surfaces | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1656088-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | Parion Sciences, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005018560-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20010034349-A1 | Methods of hydrating mucosal surfaces | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2001-10-25 | — | — | US | disclosed |
| US-6143279-A | HYDRATE LUNG MUSOUS SECRETIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-11-07 | — | — | US | disclosed |
| US-5935555-A | PHARMACEUTICAL FORMULATIONS FOR TREATING CYSTIC FIBROSIS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-08-10 | — | — | US | disclosed |
| US-5876700-A | Methods of hydrating lung mucous secretions with benzamil or phenamil | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-03-02 | — | — | US | disclosed |
| US-5656256-A | Methods of treating lung disease by an aerosol containing benzamil or phenamil | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0451130-A2 | Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization | CELTRIX PHARMACEUTICALS, INC. (US) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034349-A1 | Methods of hydrating mucosal surfaces | P2RY2, P2RY1, TRPV1 | PLAU 1058/4885SCNN1A 21/4885ALDH1A1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.